This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Antiepileptic Drug Augmentation for Treatment-Resistant Depression

Article Abstract

Letter to the Editor

Sir: The recent case report by Ketter, Callahan, and Post1 illustrating
a positive therapeutic drug/drug interaction for
treatment-resistant anxious depression is an example of outstanding
psychopharmacologic strategizing. The authors explain
their successful outcome, achieved when nefazodone was
added to alprazolam, with a pharmacokinetic model, hypothesizing
that nefazodone extended the duration of action of alprazolam
through inhibiting its degradation by the cytochrome
P450 3A3/4 system, thereby eliminating "interdose dysphoria."


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 58

Quick Links: Depression (MDD)